AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35448002 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib (12 mg daily during HSRT, adjuvant d1-14 every 3 weeks)
Number of subjects: 5
Study 35448002 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated stereotactic radiotherapy (HSRT) (25.0 Gy in 5 fractions)
Number of subjects: 5
Study 35448002 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 5
Study 35448016 — intervention group
Group type: EXPERIMENTAL
Intervention: Music interventions
Number of subjects: 200
Study 35448016 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline stress
Number of subjects: 200
Study 35448159 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS)
Number of subjects: 182
Study 35448159 — intervention group
Group type: COMPARATOR
Intervention: Abdominal radical hysterectomy (ARH)
Number of subjects: 182
Study 35449010 — intervention group
Group type: EXPERIMENTAL
Intervention: Early point-of-care ultrasound (PoCUS) (≤120 min)
Number of subjects: 888
Study 35449010 — intervention group
Group type: COMPARATOR
Intervention: Late point-of-care ultrasound (PoCUS) (>120 min)
Number of subjects: 888
Study 35449010 — intervention group
Group type: EXPERIMENTAL
Intervention: Early point-of-care ultrasound (PoCUS)
Number of subjects: 888
Study 35449028 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose quadrivalent influenza vaccine
Number of subjects: 40000
Study 35449028 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose quadrivalent influenza vaccine
Number of subjects: 40000
Study 35449030 — intervention group
Group type: EXPERIMENTAL
Intervention: BioNTech/Pfizer (BNT162b2, n=34)
Number of subjects: 86
Study 35449030 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderna (mRNA-1273, n=20)
Number of subjects: 86
Study 35449030 — intervention group
Group type: EXPERIMENTAL
Intervention: AstraZeneca (ChAdOx1 nCoV-19, n=32)
Number of subjects: 86
Study 35449030 — intervention group
Group type: COMPARATOR
Intervention: Confirmed SARS-CoV-2 infection (n=19)
Number of subjects: 86
Study 35449030 — intervention group
Group type: COMPARATOR
Intervention: Pre-pandemic group (n=20)
Number of subjects: 86
Study 35449043 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific physical activities
Number of subjects: 550
Study 35449043 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of exposure to specific activities
Number of subjects: 550
Study 35449071 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtype A (16% one-year mortality)
Number of subjects: 467
Study 35449071 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtype B (34% one-year mortality)
Number of subjects: 467
Study 35449071 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtype B (adjusted for long-term risk factors)
Number of subjects: 467
Study 35449189 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophorised Acetylcholine (ACh) at 5 concentrations (0.0001% to 1%) administered via three consecutive pulses of 0.02 mA for 10 min each
Number of subjects: 15
Study 35449247 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion group (400 mL of carbohydrate-containing fluid two hours prior to surgery)
Number of subjects: 60
Study 35449247 — intervention group
Group type: COMPARATOR
Intervention: Fasting group (fasted from midnight)
Number of subjects: 60
Study 35449247 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 35449533 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline directed oral anticoagulants (OACs) including direct oral anticoagulants (DOACs)
Number of subjects: 379
Study 35449578 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 (tegafur-gimeracil-oteracil potassium) combined with radiotherapy (61.2 Gy delivered in 34 fractions)
Number of subjects: 105
Study 35449578 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 (tegafur-gimeracil-oteracil potassium) combined with radiotherapy
Number of subjects: 105
Study 35450151 — intervention group
Group type: EXPERIMENTAL
Intervention: Care as defined by their physician, with study visits scheduled every 6 months.
Number of subjects: 0
Study 35450196 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP/FF/G (extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium)
Number of subjects: 0
Study 35450196 — intervention group
Group type: COMPARATOR
Intervention: BDP/FF (beclometasone dipropionate/formoterol fumarate)
Number of subjects: 0
Study 35450196 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP/FF/G
Number of subjects: 0
Study 35450196 — intervention group
Group type: COMPARATOR
Intervention: BDP/FF
Number of subjects: 0
Study 35450477 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35450679 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplanned DAPT discontinuation
Number of subjects: 8582
Study 35450679 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplanned DAPT discontinuation ≥3 weeks after PCI
Number of subjects: 8582
Study 35450679 — intervention group
Group type: COMPARATOR
Intervention: Planned DAPT discontinuation
Number of subjects: 8582
Study 35450679 — intervention group
Group type: COMPARATOR
Intervention: HPR on clopidogrel
Number of subjects: 8582
Study 35450750 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein(a) [Lp(a)] levels
Number of subjects: 312
Study 35450750 — intervention group
Group type: COMPARATOR
Intervention: High-intensity statin use
Number of subjects: 312
Study 35450750 — intervention group
Group type: COMPARATOR
Intervention: On-treatment low-density lipoprotein cholesterol (LDL-C)
Number of subjects: 312
Study 35450750 — intervention group
Group type: COMPARATOR
Intervention: Lipoprotein(a) levels
Number of subjects: 312
Study 35450817 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy
Number of subjects: 45
Study 35450817 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity chemotherapy
Number of subjects: 45
Study 35450906 — intervention group
Group type: EXPERIMENTAL
Intervention: D-REM programme (Community paramedicine programme)
Number of subjects: 70
Study 35450966 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CT perfusion (CTP) ischemic core estimates using rCBF <30%
Number of subjects: 101
Study 35450966 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up diffusion-weighted imaging (DWI) lesions
Number of subjects: 101
Study 35450966 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of rCBF <20% threshold for estimating ischemic core
Number of subjects: 101
Study 35450966 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric correlation between ischemic core estimate and follow-up imaging
Number of subjects: 101
Study 35450966 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant overestimation of ischemic core volume
Number of subjects: 101
Study 35451010 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoluminal vacuum therapy (EVT) using Eso-Sponge®
Number of subjects: 102
Study 35451040 — intervention group
Group type: EXPERIMENTAL
Intervention: Motorized spiral enteroscopy (MSE)
Number of subjects: 298
Study 35451176 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxelotor treatment for up to 48 weeks
Number of subjects: 45
Study 35451199 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Number of subjects: 0
Study 35451199 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulforaphane + CB-5083
Number of subjects: 0
Study 35451199 — intervention group
Group type: COMPARATOR
Intervention: CB-5083
Number of subjects: 0
Study 35451488 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 0
Study 35451488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35451899 — intervention group
Group type: EXPERIMENTAL
Intervention: ATTRv with autonomic dysfunction
Number of subjects: 2922
Study 35451899 — intervention group
Group type: COMPARATOR
Intervention: ATTRv without autonomic dysfunction
Number of subjects: 2922
Study 35451899 — intervention group
Group type: EXPERIMENTAL
Intervention: ATTRwt with autonomic dysfunction
Number of subjects: 2922
Study 35451899 — intervention group
Group type: COMPARATOR
Intervention: ATTRwt without autonomic dysfunction
Number of subjects: 2922
Study 35451922 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-Breath Washout
Number of subjects: 0
Study 35451989 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac imaging based on cardiac magnetic resonance and echocardiography
Number of subjects: 150
Study 35451989 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating biomarkers
Number of subjects: 150
Study 35452178 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care with transfusions and surgical interventions
Number of subjects: 0
Study 35452178 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular hematology care with visits at least every 6 months
Number of subjects: 0
Study 35452178 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer disease-modifying therapies being developed and studied
Number of subjects: 0
Study 35452195 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive Therapy (ECT)
Number of subjects: 0
Study 35452519 — intervention group
Group type: EXPERIMENTAL
Intervention: Leronlimab (CCR5-binding antibody), specific dosage and duration not mentioned
Number of subjects: 0
Study 35452519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35452785 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents with depression pre-pandemic
Number of subjects: 166
Study 35452785 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (HVs) pre-pandemic
Number of subjects: 166
Study 35452785 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents with depression during the pandemic
Number of subjects: 166
Study 35452785 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (HVs) during the pandemic
Number of subjects: 166
Study 35452785 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents with depression
Number of subjects: 166
Study 35452808 — intervention group
Group type: EXPERIMENTAL
Intervention: Parsley drink containing apigenin-7-O-(2"-O-apiosyl)glucoside
Number of subjects: 0
Study 35452808 — intervention group
Group type: COMPARATOR
Intervention: Apigenin
Number of subjects: 0
Study 35453059 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) performed during hospitalization
Number of subjects: 71
Study 35453059 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) performed 2-3 months after discharge
Number of subjects: 71
Study 35453059 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) score
Number of subjects: 71
Study 35453059 — intervention group
Group type: EXPERIMENTAL
Intervention: Total number of B-lines
Number of subjects: 71
Study 35453059 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) findings in patients with ARDS
Number of subjects: 71
Study 35453064 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel (median maximum dose 6.0 mg/day)
Number of subjects: 1451
Study 35453064 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 1451
Study 35454839 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive physical plasma (NIPP) treatment
Number of subjects: 20
Study 35454839 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPP treatment
Number of subjects: 20
Study 35455592 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane exposure before 45 weeks corrected gestational age
Number of subjects: 139
Study 35455660 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antiarrhythmic agents (amiodarone, vernakalant, ibutilide)
Number of subjects: 3053
Study 35455660 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 3053
Study 35455660 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernakalant
Number of subjects: 3053
Study 35455660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide
Number of subjects: 3053
Study 35455660 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial flutter
Number of subjects: 3053
Study 35455660 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of symptoms associated with AF (<24 h)
Number of subjects: 3053
Study 35455660 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of previous electrical cardioversion
Number of subjects: 3053
Study 35456277 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological music therapy for 3 months
Number of subjects: 25
Study 35456277 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study 35456481 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35457335 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based physical activity intervention for 12 weeks
Number of subjects: 62
Study 35459113 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker assessment aided by mHealth
Number of subjects: 273
Study 35459113 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker assessment for danger signs (excluding hypothermia)
Number of subjects: 273
Study 35459113 — intervention group
Group type: COMPARATOR
Intervention: Physician assessment
Number of subjects: 273
Study 35459238 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigator-supported remote symptom monitoring
Number of subjects: 0
Study 35459238 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 35459672 — intervention group
Group type: EXPERIMENTAL
Intervention: Socially disadvantaged patients (EPICES score ≥30.17)
Number of subjects: 0
Study 35459672 — intervention group
Group type: COMPARATOR
Intervention: Patients without specified social vulnerability
Number of subjects: 0
Study 35459680 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse oximeter measurements (preductal and postductal)
Number of subjects: 2000
Study 35459679 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care acceptance group (n=20)
Number of subjects: 40
Study 35459679 — intervention group
Group type: COMPARATOR
Intervention: Early palliative care refusal group (n=20)
Number of subjects: 40
Study 35459679 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (n=40)
Number of subjects: 40
Study 35459718 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy (LLT)
Number of subjects: 462
Study 35459718 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin and ezetimibe
Number of subjects: 462
Study 35459929 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum BDNF (sBDNF) levels
Number of subjects: 969
Study 35459929 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes and low sBDNF levels or BDNF Met/Met genotype
Number of subjects: 969
Study 35459929 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes with sBDNF in the lowest tertile or BDNF Met/Met genotype
Number of subjects: 969
Study 35460043 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide (10 μg sc)
Number of subjects: 30
Study 35460043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 35460313 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain management at haemophilia treatment centres (HTC)
Number of subjects: 343
Study 35460313 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of depression/anxiety at haemophilia treatment centres (HTC)
Number of subjects: 343
Study 35460313 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease severity
Number of subjects: 343
Study 35460313 — intervention group
Group type: COMPARATOR
Intervention: HTC survey responses
Number of subjects: 343
Study 35460412 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian stimulation during IUI treatment
Number of subjects: 492
Study 35460412 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal ovarian response
Number of subjects: 492
Study 35460412 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum AMH
Number of subjects: 492
Study 35460412 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI and serum basal FSH
Number of subjects: 492
Study 35460412 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, BMI, and serum FSH
Number of subjects: 492
Study 35460412 — intervention group
Group type: EXPERIMENTAL
Intervention: AMH addition to prediction models
Number of subjects: 492
Study 35460497 — intervention group
Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection (RCI; Acthar® Gel); 80 U subcutaneously twice weekly for 12 weeks
Number of subjects: 15
Study 35460583 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to medical insurance
Number of subjects: 99
Study 35460583 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a mobile phone
Number of subjects: 99
Study 35460583 — intervention group
Group type: EXPERIMENTAL
Intervention: History of more severe childhood trauma
Number of subjects: 99
Study 35460583 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall well-being
Number of subjects: 99
Study 35460850 — intervention group
Group type: EXPERIMENTAL
Intervention: Young-old patients (60-69 years)
Number of subjects: 2337
Study 35460850 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-old patients (70-79 years)
Number of subjects: 2337
Study 35460850 — intervention group
Group type: EXPERIMENTAL
Intervention: Very old patients (≥80 years)
Number of subjects: 2337
Study 35460850 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality by age group
Number of subjects: 2337
Study 35460884 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartLogic multisensor index and alerts
Number of subjects: 200
Study 35460882 — intervention group
Group type: EXPERIMENTAL
Intervention: Lonely (total UCLA Three-Item Loneliness Scale score ≥5)
Number of subjects: 454
Study 35460882 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty (Liver Frailty Index ≥4.4)
Number of subjects: 454
Study 35460882 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 454
Study 35460882 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 454
Study 35460882 — intervention group
Group type: EXPERIMENTAL
Intervention: Not working
Number of subjects: 454
Study 35460882 — intervention group
Group type: EXPERIMENTAL
Intervention: Not in a committed partnership
Number of subjects: 454
Study 35460976 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirogacestat (PF-0308401)
Number of subjects: 0
Study 35460976 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-secretase inhibitor AL102
Number of subjects: 0
Study 35460976 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-catenin inhibitor Tegavivint (BC2059)
Number of subjects: 0
Study 35461007 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuro-prosthetic leg use
Number of subjects: 0
Study 35461007 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 35461085 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid misuse
Number of subjects: 3794
Study 35461085 — intervention group
Group type: EXPERIMENTAL
Intervention: Existing evidence-based substance use interventions
Number of subjects: 3794
Study 35461262 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) scopolamine administered over the course of 2 weeks with three blinded infusions.
Number of subjects: 0
Study 35461262 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered over the course of 2 weeks with three blinded infusions.
Number of subjects: 0
Study 35461300 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based behavioral interventions (EBI) for methamphetamine use
Number of subjects: 600
Study 35462388 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-ECT evaluation practices including complete blood count, serum electrolytes, renal function analysis, cardiovascular assessment, psychiatric scales, and cognitive assessment.
Number of subjects: 18
Study 35462754 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Breast MRI (CE-BMRI)
Number of subjects: 778
Study 35462754 — intervention group
Group type: COMPARATOR
Intervention: X-ray Mammography (XRM)
Number of subjects: 778
Study 35463015 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDA International Registry
Number of subjects: 290
Study 35463344 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Prostate Health Index Density (mPHI)
Number of subjects: 278
Study 35463344 — intervention group
Group type: COMPARATOR
Intervention: Prostate Health Index (PHI)
Number of subjects: 278
Study 35463344 — intervention group
Group type: COMPARATOR
Intervention: Prostate Health Index Density (PHID)
Number of subjects: 278
Study 35463750 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor-derived Cell Free DNA (dd-cfDNA) levels measured in patients undergoing routine coronary angiography
Number of subjects: 94
Study 35463775 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel HAMIOT risk score
Number of subjects: 12043
Study 35463834 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Behavior in School-aged Children (HBSC) questionnaire
Number of subjects: 50
Study 35463834 — intervention group
Group type: COMPARATOR
Intervention: Travel diary
Number of subjects: 50
Study 35463896 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary in-the-bag intraocular lens (IOL) implantation
Number of subjects: 23
Study 35463896 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior capsulorhexis or capsulectomy with a diameter of 3.0 to 4.0 mm
Number of subjects: 23
Study 35463939 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 64
Study 35463939 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 64
Study 35463939 — intervention group
Group type: EXPERIMENTAL
Intervention: FMT
Number of subjects: 64
Study 35463939 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients with rCDI
Number of subjects: 64
Study 35463939 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective treatment (including rescue FMT)
Number of subjects: 64
Study 35464004 — intervention group
Group type: EXPERIMENTAL
Intervention: Myosteatosis diagnosed during acute COVID-19
Number of subjects: 97
Study 35464004 — intervention group
Group type: EXPERIMENTAL
Intervention: Myosteatosis (lowest sex- and age-specific tertile of SM-RA)
Number of subjects: 97
Study 35464483 — intervention group
Group type: EXPERIMENTAL
Intervention: Th2-oriented immune serum from alum-adjuvanted S1 subunit vaccines
Number of subjects: 11
Study 35464483 — intervention group
Group type: EXPERIMENTAL
Intervention: Th2-oriented immune serum from inactivated SARS-CoV-2 vaccination
Number of subjects: 11